Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.23p
   
  • Change Today:
      0.000p
  • 52 Week High: 0.28
  • 52 Week Low: 0.19
  • Currency: UK Pounds
  • Shares Issued: 2,148.96m
  • Volume: 27,390
  • Market Cap: £4.94m

Latest ShareCast News

Theracryf upbeat on initial toxicology data from lead programme

By Josh White

Date: Thursday 14 May 2026

(Sharecast News) - Theracryf said on Thursday that initial toxicology data from its lead Ox-1 blocker addiction programme showed the drug was well tolerated at very high doses, as clinical trial-enabling work continued ahead of plan.

TheraCryf manufactures over 2kg of Ox-1 receptor antagonist substance

By Josh White

Date: Monday 20 Apr 2026

(Sharecast News) - TheraCryf said on Monday that it has successfully manufactured clinical-grade material for its lead Ox-1 receptor antagonist, marking a key step towards initiating human trials.

TheraCryf lead Ox-1 programme advances to final toxicology studies

By Josh White

Date: Monday 23 Mar 2026

(Sharecast News) - TheraCryf said on Monday that its lead Ox-1 receptor antagonist programme for addiction had advanced to final toxicology studies, keeping the biotech group on track to begin human clinical trials by the end of 2026.

TheraCryf allowed Canadian patent, reports precl... 26-Jan-2026 ShareCast
TheraCryf signs deal for Ox-1 addiction treatmen... 12-May-2025 ShareCast
Evgen upbeat on start of glioblastoma research p... 26-Oct-2023 ShareCast
Evgen Pharma doses first volunteers in SFX-01 tr... 16-Nov-2022 ShareCast
Evgen starts recruiting volunteers for trial of ... 12-Oct-2022 ShareCast
Evgen agrees fresh licensing deal with Spanish i... 18-Jan-2022 ShareCast
Evgen pleased with preclinical data on SFX-01 13-Jul-2021 ShareCast
Evgen 'surprised and disappointed' by findings i... 09-Jul-2021 ShareCast
Evgen upbeat on new data on potential breast can... 14-Jun-2021 ShareCast
Evgen appoints Helen Kuhlman as chief business o... 22-Mar-2021 ShareCast
Evgen Covid-19 trial given all-clear on safety a... 11-Mar-2021 ShareCast
Evgen makes progress with recruitment in 'STAR' ... 17-Feb-2021 ShareCast
Evgen announces positive preclinical data for SF... 22-Jan-2021 ShareCast
Evgen reports 'highly positive' data from SFX-01... 21-Jan-2021 ShareCast
Evgen Pharma makes progress with 'STAR' trial re... 19-Jan-2021 ShareCast
Evgen Pharma performs in line with forecasts in ... 10-Dec-2020 ShareCast
Evgen doses first patients in 'STAR' respiratory... 23-Nov-2020 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.23p
Change Today 0.000p
% Change 0.00 %
52 Week High 0.28
52 Week Low 0.19
Volume 27,390
Shares Issued 2,148.96m
Market Cap £4.94m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
13.79% above the market average13.79% above the market average13.79% above the market average13.79% above the market average13.79% above the market average
90.24% above the sector average90.24% above the sector average90.24% above the sector average90.24% above the sector average90.24% above the sector average
Price Trend
86.93% below the market average86.93% below the market average86.93% below the market average86.93% below the market average86.93% below the market average
72.73% below the sector average72.73% below the sector average72.73% below the sector average72.73% below the sector average72.73% below the sector average
Income Not Available
Growth Not Available

Theracryf Dividends

No dividends found

Trades for 27-May-2026

Time Volume / Share Price
15:44 500 @ 0.24p
15:44 4,167 @ 0.24p
15:44 500 @ 0.24p
15:44 2,223 @ 0.22p
15:44 20,000 @ 0.22p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page